Akari Therapeutics
24 West 40th Street. 8th Floor
New York
New York
10018
United States
Tel: 1-646-350-0702
Fax: 1-646-843-9352
Website: http://akaritx.com/
161 articles about Akari Therapeutics
-
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
3/5/2024
Akari Therapeutics, Plc and Peak Bio Inc. announce a definitive agreement to merge as equals in an all-stock transaction.
-
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
3/5/2024
Akari Therapeutics, Plc and Peak Bio Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction.
-
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
1/2/2024
Akari Therapeutics, Plc announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million.
-
Akari Therapeutics to Present at Biotech Showcase 2024
12/14/2023
Akari Therapeutics, Plc announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024.
-
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
12/1/2023
Akari Therapeutics, Plc today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. to the Akari Board of Directors.
-
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
11/16/2023
Akari Therapeutics, Plc , today announced the presentation of progress in the development of long-acting PASylated ® -nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD) in a poster at the 4th Annual Dry AMD Therapeutic Development conference.
-
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
11/6/2023
Akari Therapeutics, Plc today announced that Chief Scientific Officer Miles Nunn will present a poster titled Development of PASylated ® -Nomacopan for Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD) at the 4th Annual Dry AMD Therapeutic Development conference.
-
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
9/29/2023
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced financial results and highlights for the first half of 2023, ended June 30th.
-
Akari Therapeutics to Present at Emerging Growth Conference
9/27/2023
Akari Therapeutics, Plc today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023.
-
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
9/21/2023
Akari Therapeutics, Plc today announced that it has entered into definitive purchase agreements with certain existing investors, including Akari Chairman Dr. Ray Prudo and President and CEO Rachelle Jacques, for a private placement of its equity securities.
-
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
9/19/2023
Akari Therapeutics, Plc today announced the company will host a virtual key opinion leader event on October 19, 2023 at 11:30 am ET to discuss the patient care landscape for hematopoietic stem cell transplant-related thrombotic microangiopathy.
-
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
9/5/2023
Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases announced the company has received written notification from Nasdaq that it has regained compliance with the minimum bid price requirement.
-
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
8/18/2023
Akari Therapeutics, Plc today announced the establishment of a Boston Seaport area office that is the company’s U.S. headquarters
-
Akari Therapeutics, Plc Announces ADS Ratio Change
8/15/2023
Akari Therapeutics, Plc today announced that Akari will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing one hundred ordinary shares to a new ratio of one ADS representing two thousand ordinary shares.
-
Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs
8/2/2023
Akari Therapeutics, Plc , today announced the appointment of Beth-Anne Lang, as Senior Vice President, Regulatory Affairs.
-
Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation
7/27/2023
Akari Therapeutics, Plc today announced that the European Commission granted orphan drug designation to nomacopan as a treatment in hematopoietic stem cell transplantation following the European Medicines Agency positive opinion in June.
-
Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer
7/19/2023
Akari Therapeutics, Plc today announced the appointment of experienced life sciences executive Wendy DiCicco as interim Chief Financial Officer (CFO).
-
Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA
7/13/2023
Akari Therapeutics, Plc today announced updates in the development programs investigating nomacopan in pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).
-
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
7/11/2023
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced updates on the development of long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA).
-
Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation
7/6/2023
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the company’s application for orphan drug designation for nomacopan as a treatment in hematopoietic stem cell transplantation.